Oncology

#Arsenal Biosciences #Cell therapy #Fundraising #Oncology #Solid tumours

Cell therapy developer ArsenalBio raises $325 million

Arsenal Biosciences has closed an oversubscribed $325 million Series C financing round to support its development of CAR T-cell therapies for solid tumours. The funding round included new investors ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures (NVIDIA’s venture capital arm), Luma Group, funds and accounts advised by… Read More

#Business & Investment #News

T cells attack a cancer cell
#Assay development optimisation & technology #Cancer immunotherapy #Cancer research #Immuno-oncology #Immunotherapy #Oncology #Phase III trial

New podcast: The consistency and value of immunotherapy

This is the latest episode of the free DDW narrated podcast, titled “How technology is impacting drug discovery”, which covers two articles written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Immunotherapy offers survival extension for brain tumour patients and The evolution of assays for… Read More

#News

Genomics
#Cancer drug targets #Gene mutation #Genetics / genomics #Oncology #Wellcome Sanger Institute

‘Cancer-protection’ gene study reveals potential cancer drug targets

Scientists have pinpointed thousands of genetic changes in a gene that may increase a person’s risk of developing breast and ovarian cancer and also identified new potential therapeutic targets. Researchers from the Wellcome Sanger Institute and their collaborators focused on the ‘cancer protection’ gene RAD51C, known… Read More

#Cancer Research #News #Trending News

T cell attacking cancer cell
#CDR-Life #Immunotherapy #Oncology #Solid tumours #T cell engagers

CDR-Life progresses pipeline of T cell engagers for solid tumours

CDR-Life has announced new developments to its programme of antibody-based T cell engagers (TCE) targeting intracellular tumour antigens MAGE-A4 and PRAME via the major histocompatibility complex. The first patient has been dosed with CDR404, a novel, bispecific and bivalent antibody fragment-based TCE targeting MAGE-A4. Read More

#Cancer Research #News

Cancer metastasis
#Cancer therapeutics #Clinical trials #ESMO #Events #Oncology

The latest breakthroughs in cancer research

The European Society for Medical Oncology (ESMO) Congress 2024 took place in Barcelona, Spain, 13-17 September 2024, and featured some significant breakthroughs in cancer drug discovery. NIAGARA Phase III trial AstraZeneca presented positive results from its NIAGARA Phase III trial, a global study to evaluate the… Read More

#Cancer Research #News #Trending News

#AI #Career #Clinical trials #Drug discovery #Infectious diseases #Meet the Researcher #Oncology #Poolbeg Pharma

Meet the researcher: Liam Tremble

DDW’s Megan Thomas looks at a day in the life of Liam Tremble, Principal Scientist at Poolbeg Pharma. 1. Where do you work, and can you tell us what you’re working on at the moment?   I work at Poolbeg Pharma, where we are developing novel treatments for diseases with unmet… Read More

#Exclusive Content #Opinion

X-ray showing colon cancer
#Colorectal cancer #Janssen #Monoclonal antibodies #Oncology #Phase II trial

Metastatic colon cancer: 49% response for combination therapy

Janssen-Cilag has shared new data from the Phase Ib/II OrigAMI-1 study at the European Society of Medical Oncology (ESMO) 2024 Congress. The results show that amivantamab combined with chemotherapy demonstrated promising antitumour activity in patients with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) who have not… Read More

#Cancer Research #News #Trending News

Genetics
#Africa #Childhood cancer #Nanopore sequencing #Oncology #Oxford Nanopore Technologies #Paediatrics

Consortium hopes to improve childhood cancer survival in Africa

Oxford Nanopore Technologies has joined the PROGRESS study to support improved outcomes for childhood leukaemias in Ghana. The consortium so far includes Yemaachi Biotech, Pediatric Oncology Units at Korle Bu Teaching Hospital, Komfo Anokye Teaching Hospital and Greater Accra Regional Hospital, and institutions like Newcastle University,… Read More

#Cancer Research #News

Saline intravenous (iv) drip in a child's hand
#Cancer Research Horizons #Drug discovery #LifeArc #Oncology #Paediatrics

Research consortium to focus on drug discovery for paediatric cancers

With an initial investment of £28 million in resources and funding, LifeArc and Cancer Research UK have launched a new initiative to develop medicines exclusively for children’s and young people’s cancers. C-Further will bring together researchers, clinicians, scientists and industry to provide support, finance and expertise. Read More

#Cancer Research #News

Lungs
#Boehringer Ingelheim #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology #Phase I trial

Over 60% response in lung cancer tumours with rare mutation

Boehringer Ingelheim has reported positive results from its Phase Ib primary analysis of Cohort 1 of the Beamion LUNG-1 trial evaluating zongertinib (BI 1810631) in pre-treated patients with advanced non-small cell lung cancer (NSCLC) with activating HER2 mutations. Zongertinib, an investigational oral HER2 tyrosine kinase inhibitor… Read More

#Cancer Research #News #Trending News

Human brain
#Brain cancer #Dana-Farber Cancer Institute #Drug repurposing #Oncology #The Institute of Cancer Research

Breast cancer drug could treat rare childhood brain tumours

Ribociclib – a drug already used to treat breast cancer – may help slow the growth of diffuse hemispheric glioma (DHG), new research has found. A team of scientists from The Institute of Cancer Research, London and the Dana-Farber Cancer Institute, Boston, USA, have uncovered clues… Read More

#Cancer Research #Editor's Choice #News

Prostate cancer cells
#Australia #Flinders University #Oncology #Prostate cancer #Protein inhibitor

Potential breakthrough in treating prostate cancer

Researchers from Flinders University and University of South Australia have unveiled a promising new strategy that could be used to treat the most aggressive forms of prostate cancer. This study, published in British Journal of Cancer, explores the role of a novel drug, CDKI-73, to tackle… Read More

#Cancer Research #Editor's Choice #News

Liver cancer
#Cell therapy #FDA #Grit Biotechnology #Oncology #Solid tumours

FDA clears genetically engineered TIL therapy for solid tumour trials

Grit Biotechnology has received investigational new drug (IND) approval from the US Food and Drug Administration (FDA) for its genetically engineered tumour-infiltrating lymphocyte (TIL) product GT201. The therapy is now approved by both the FDA and China Center for Drug Evaluation (CDE) to enter clinical trials in both countries for… Read More

#Cancer Research #News #Regulatory

#Clinical trial #Colorectal cancer #NuCana #Oncology

Colorectal cancer study to be discontinued

NuCana has revealed that the NuTide:323 colorectal cancer study is being discontinued following a pre-planned initial analysis and recommendation from the NuTide:323 Study Steering Committee. The Steering Committee believed that the combination of NUC-3373 with leucovorin, irinotecan and bevacizumab (NUFIRI+bev) was unlikely to achieve the study’s… Read More

#News